Signal Tree Financial Partners LLC Acquires New Position in Abbott Laboratories $ABT

Key Points

• Signal Tree Financial Partners LLC has acquired a new position in Abbott Laboratories, purchasing 2,604 shares valued at approximately $354,000 in Q2.
• Abbott Laboratories reported earnings of $1.26 per share for the recent quarter, meeting analyst expectations, with a revenue increase of 7.4% compared to the previous year.
• The company declared a quarterly dividend of $0.59 per share, which will be paid on November 17th, representing an annualized yield of 1.8%.

Signal Tree Financial Partners LLC acquired a new stake in shares of Abbott Laboratories (NYSE:ABT - Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 2,604 shares of the healthcare product maker's stock, valued at approximately $354,000.

A number of other hedge funds also recently made changes to their positions in the stock. Signet Financial Management LLC grew its stake in shares of Abbott Laboratories by 6.5% during the 2nd quarter. Signet Financial Management LLC now owns 3,066 shares of the healthcare product maker's stock valued at $417,000 after acquiring an additional 188 shares during the period. Verum Partners LLC grew its stake in shares of Abbott Laboratories by 50.3% during the 2nd quarter. Verum Partners LLC now owns 3,348 shares of the healthcare product maker's stock valued at $455,000 after acquiring an additional 1,120 shares during the period. Legacy Solutions LLC grew its stake in shares of Abbott Laboratories by 8.4% during the 2nd quarter. Legacy Solutions LLC now owns 1,842 shares of the healthcare product maker's stock valued at $251,000 after acquiring an additional 142 shares during the period. Mather Group LLC. grew its stake in shares of Abbott Laboratories by 16.5% during the 2nd quarter. Mather Group LLC. now owns 25,596 shares of the healthcare product maker's stock valued at $3,481,000 after acquiring an additional 3,623 shares during the period. Finally, Foster Victor Wealth Advisors LLC grew its stake in shares of Abbott Laboratories by 3.5% during the 2nd quarter. Foster Victor Wealth Advisors LLC now owns 3,681 shares of the healthcare product maker's stock valued at $490,000 after acquiring an additional 124 shares during the period. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Stock Performance

NYSE:ABT opened at $133.80 on Thursday. The stock's fifty day moving average is $130.69 and its 200 day moving average is $131.17. Abbott Laboratories has a fifty-two week low of $110.86 and a fifty-two week high of $141.23. The firm has a market capitalization of $232.87 billion, a PE ratio of 16.77, a PEG ratio of 2.58 and a beta of 0.69. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, meeting the consensus estimate of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The company had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.01 billion. During the same quarter in the prior year, the firm posted $1.14 EPS. Abbott Laboratories's quarterly revenue was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. On average, sell-side analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Investors of record on Wednesday, October 15th will be issued a dividend of $0.59 per share. This represents a $2.36 annualized dividend and a yield of 1.8%. The ex-dividend date is Wednesday, October 15th. Abbott Laboratories's dividend payout ratio is presently 29.57%.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on ABT shares. Morgan Stanley boosted their price target on Abbott Laboratories from $127.00 to $137.00 and gave the stock an "equal weight" rating in a report on Tuesday, July 15th. Leerink Partners started coverage on Abbott Laboratories in a report on Monday, June 16th. They issued a "market perform" rating and a $143.00 price target on the stock. Royal Bank Of Canada boosted their price target on Abbott Laboratories from $145.00 to $147.00 and gave the stock an "outperform" rating in a report on Tuesday, July 15th. Raymond James Financial lowered their price target on Abbott Laboratories from $142.00 to $141.00 and set an "outperform" rating on the stock in a report on Friday, July 18th. Finally, BTIG Research lowered their price target on Abbott Laboratories from $148.00 to $145.00 and set a "buy" rating on the stock in a report on Friday, July 18th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $145.22.

Insider Buying and Selling

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the stock in a transaction on Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the sale, the chief financial officer owned 51,003 shares in the company, valued at $6,862,453.65. This trade represents a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.46% of the stock is owned by company insiders.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.